CompletedPhase 2NCT02017912

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

Studying Amyotrophic Lateral Sclerosis (ALS)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brainstorm-Cell Therapeutics
Principal Investigator
Merit Cudkowicz, MD
Massachusetts General Hospital
Intervention
Nurown MSC-NTF cells(biological)
Enrollment
48 enrolled
Eligibility
18-75 years · All sexes
Timeline
20142016

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02017912 on ClinicalTrials.gov

Other trials for Amyotrophic Lateral Sclerosis (ALS)

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic Lateral Sclerosis (ALS)

← Back to all trials